Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis

Biochemical Pharmacology

Volumn 80, Issue 10, 2010, Pages 1478-1486

  Jones, Deuan C ^a   Hallyburton, Irene ^a   Stojanovski, Laste ^a   Read, Kevin D ^a   Frearson, Julie A ^a   Fairlamb, Alan H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

African trypanosomiasis; Phenotypic screening; Target identification; Target validation; U50,488

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; PENTAMIDINE; RESAZURIN; SURAMIN; ANTIPROTOZOAL AGENT; KAPPA OPIATE RECEPTOR; LIGAND;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; DIPLOIDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ENERGY METABOLISM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCREENING; TRYPANOSOMA BRUCEI; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SENSITIVITY; FIBROBLAST; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PARASITOLOGY; PROCEDURES; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANIMALS; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; DRUG DISCOVERY; FIBROBLASTS; HUMANS; LIGANDS; MICE; PARASITIC SENSITIVITY TESTS; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 77957016594     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.038     Document Type: Article

References (31)

1. Garcia A., Courtin D., Solan P., Koffi M., Jamonnea V. Human African trypanosomiasis: connecting parasite and host genetics. Trends Parasitol 2006, 22:405-409.
2. Stuart K.D., Brun R., Croft S.L., Fairlamb A.H., Gurtler R.E., McKerrow J.H., et al. Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest 2008, 118:1301-1310.
3. Renslo A.R., McKerrow J.H. Drug discovery and development for neglected parasitic diseases. Nat Chem Biol 2006, 2:701-710.
4. Pépin J., Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994, 33:1-47.
5. Priotto G., Kasparian S., Mutombo W., Ngouama D., Ghorashian S., Arnold U., et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009, 374:56-64.
6. Thuita J.K., Karanja S.M., Wenzler T., Mdachi R.E., Ngotho J.M., Kagira J.M., et al. Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis. Acta Trop 2008, 108:6-10.
7. Frearson J.A., Wyatt P.A., Gilbert I.H., Fairlamb A.H. Target assessment for antiparasitic drug discovery. Trends Parasitol 2007, 23:589-595.
8. Mackey Z.B., Baca A.M., Mallari J.P., Apsel B., Shelat A., Hansell E.J., et al. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des 2006, 67:355-363.
9. Hopkins A.L. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008, 4:682-690.
10. Hirumi H., Hirumi K. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol 1989, 75:985-989.
11. Zhang J.H., Chung T.D.Y., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999, 4:67-73.
12. Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J. Basic local alignment search tool. J Mol Biol 1990, 215:403-410.
13. ® assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro. Acta Trop 1997, 68:139-147.
14. O'Brien J., Wilson I., Orton T., Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000, 267:5421-5426.
15. Likeufack A.C.L., Brun R., Fomena A., Truc P. Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004. Acta Trop 2006, 100:11-16.
16. Giffin B.F., McCann P.P. Physiological activation of the mitochondrion and the transformation capacity of DFMO induced intermediate and short stumpy bloodstream form trypanosomes. Am J Trop Med Hyg 1989, 40:487-493.
17. Wilkinson S.R., Taylor M.C., Horn D., Kelly J.M., Cheeseman I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 2008, 105:5022-5027.
18. Sokolova A.Y., Wyllie S., Patterson S., Oza S.L., Read K.D., Fairlamb A.H. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob Agents Chemother 2010, 54:2893-2900.
19. Arcamone F., Cassinel G., Fantini G., Grein A., Orezzi P., Pol C., et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var caesius. Biotechnol Bioeng 1969, 11:1101-1110.
20. Caffrey C.R., Steverding D., Swenerton R.K., Kelly B., Walshe D., Debnath A., et al. Bis-acridines as lead anti-parasitic agents: structure activity analysis of a discrete compound library in vitro. Antimicrob Agents Chemother 2007, 51:2164-2172.
21. Girault S., Grellier P., Berecibar A., Maes L., Mouray E., Lemiere P., et al. Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker. J Med Chem 2000, 43:2646-2654.
22. Rodrigues J.R., de Dominguez N.G. Plasmodium berghei: in vitro and in vivo activity of dequalinium. Exp Parasitol 2007, 115:19-24.
23. Lardy H.A., Johnson D., McMurray W.C. Antibiotics as tools for metabolic studies. I. A survey of toxic antibiotics in respiratory, phosphorylative and glycolytic systems. Arch Biochem Biophys 1958, 78:587-597.
24. Jordan M.A., Himes R.H., Wilson L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res 1985, 45:2741-2747.
25. Frearson J.A., Brand S., McElroy S.P., Cleghorn L.A.T., Smid O., Stojanovski L., et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 2010, 464:728-732.
26. Turner C.M.R., McLellan S., Lindergard L.A.G., Bisoni L., Tait A., MacLeod A. Human infectivity trait in Trypanosoma brucei: stability, heritability and relationship to sra expression. Parasitology 2004, 129:445-454.
27. Sienkiewicz N., Jaroslawski S., Wyllie S., Fairlamb A.H. Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. Mol Microbiol 2008, 69:520-533.
28. Brenk R., Schipani A., James D., Krasowski A., Gilbert I.H., Frearson J., et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem 2008, 3:435-444.
29. Vonvoigtlander P.F., Lahti R.A., Ludens J.H. U-50,488-a selective and structurally novel non-mu-(kappa) opioid agonist. J Pharmacol Exp Ther 1983, 224:7-12.
30. Martin R.E., Marchetti R.V., Cowan A.I., Howitt S.M., Broer S., Kirk K. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 2009, 325:1680-1682.
31. Sanchez C.P., Stein W.D., Lanzer M. Is PfCRT a channel or a carrier? Two competing models explaining chloroquine resistance in Plasmodium falciparum. Trends Parasitol 2007, 23:332-339.